AgilVax company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

agilvax.com

Founded Year

2011

Stage

Series A - IV | Alive

Total Raised

$5.55M

Last Raised

$1.4M | 2 yrs ago

About AgilVax

Agilvax is a biotechnology company employing a vaccine discovery platform to develop safe and efficacious vaccines for infectious diseases and chronic conditions. The platform is based on virus-like particles (VLP) derived from RNA bacteriophages engineered to incorporate vaccine components necessary for the rapid identification of successful candidates.

AgilVax Headquarter Location

5901 Indian School Road NE

Albuquerque, New Mexico, 87110,

United States

505-200-9541

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AgilVax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AgilVax is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

AgilVax Patents

AgilVax has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Monoclonal antibodies
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/30/2018

7/13/2021

Monoclonal antibodies, Clusters of differentiation, Experimental cancer drugs, Immune system, Transcription factors

Grant

Application Date

4/30/2018

Grant Date

7/13/2021

Title

Related Topics

Monoclonal antibodies, Clusters of differentiation, Experimental cancer drugs, Immune system, Transcription factors

Status

Grant

Latest AgilVax News

AgilVax Progress Triggers $1.2 Million SBIR Fast-Track Grant to Advance Antibody-Based Therapy

Aug 18, 2020

AgilVax Progress Triggers $1.2 Million SBIR Fast-Track Grant to Advance Antibody-Based Therapy Drug Genius Staff Writer ALBUQUERQUE, N.M.–(BUSINESS WIRE)– AgilVax, Inc ., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics to treat multiple types of cancer, announced today that the company has triggered Phase II funding worth $1.2 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Cancer Institute (NCI). The funding will be used to conduct a preclinical efficacy study, manufacturing stability studies and a nonclinical toxicology study for AX09, a virus-like-particle (VLP) therapeutic vaccine. AgilVax successfully achieved its goals from the earlier phases allowing the final portion of the grant to be awarded. AgilVax has three development programs targeting xCT, a cystine-glutamate antiporter: (1) an antibody-drug conjugate (xCT-mAb-ADC), (2), a conjugated radiopharmaceutical and (3) AX09. Oxidative stress leads to enhanced induction of xCT, which regulates cysteine intake, stimulates the conversion of cysteine and subsequent glutathione (GSH) synthesis. xCT expression is low in normal cells but elevated in numerous cancer types corresponding to increases in intracellular reactive oxygen species (ROS). Numerous cancer types are highly resistant to traditional therapies due to oxidative stress induced by cancer cell metabolism. “We are delighted to receive this grant award from the National Cancer Institute to advance the development of our antibody-based therapeutic program,” said Joseph Patti, Ph.D., president and chief executive officer of Agilvax and the Principal Investigator of the award. “Targeting redox-sensitive pathways and a protein that is upregulated in tumors that possess NFR2/KEAP1 or KRAS mutations, offers great promise for cancer therapy and AgilVax is poised to establish a new class of treatment for tough to treat cancers.” About AgilVax AgilVax discovers and develops antibody-based therapeutics for the treatment of various cancers targeting xCT (SLC7A11), a cystine-glutamate antiporter. xCT is over expressed on many different tumor types including breast, colorectal, lung, pancreatic, and hepatocellular cancers. The Company has headquarters in Albuquerque, New Mexico and labs at JLABS @ TMC in Houston, Texas. Contacts

  • When was AgilVax founded?

    AgilVax was founded in 2011.

  • Where is AgilVax's headquarters?

    AgilVax's headquarters is located at 5901 Indian School Road NE, Albuquerque.

  • What is AgilVax's latest funding round?

    AgilVax's latest funding round is Series A - IV.

  • How much did AgilVax raise?

    AgilVax raised a total of $5.55M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.